- Home
- RXT vs CRVS Comparison
RXT vs CRVS Comparison
Compare RXT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXT
- CRVS
- Stock Information
- Founded
- RXT 1998
- CRVS 2014
- Country
- RXT United States
- CRVS United States
- Employees
- RXT N/A
- CRVS N/A
- Industry
- RXT EDP Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- RXT Technology
- CRVS Health Care
- Exchange
- RXT Nasdaq
- CRVS Nasdaq
- Market Cap
- RXT 280.1M
- CRVS 305.4M
- IPO Year
- RXT 2020
- CRVS 2016
- Fundamental
- Price
- RXT $1.26
- CRVS $5.75
- Analyst Decision
- RXT Hold
- CRVS Strong Buy
- Analyst Count
- RXT 5
- CRVS 4
- Target Price
- RXT $1.58
- CRVS $15.00
- AVG Volume (30 Days)
- RXT 764.7K
- CRVS 518.7K
- Earning Date
- RXT 08-07-2025
- CRVS 08-07-2025
- Dividend Yield
- RXT N/A
- CRVS N/A
- EPS Growth
- RXT N/A
- CRVS N/A
- EPS
- RXT N/A
- CRVS N/A
- Revenue
- RXT $2,693,100,000.00
- CRVS N/A
- Revenue This Year
- RXT N/A
- CRVS N/A
- Revenue Next Year
- RXT $1.48
- CRVS N/A
- P/E Ratio
- RXT N/A
- CRVS N/A
- Revenue Growth
- RXT N/A
- CRVS N/A
- 52 Week Low
- RXT $1.00
- CRVS $2.54
- 52 Week High
- RXT $3.41
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- RXT 52.70
- CRVS 65.10
- Support Level
- RXT $1.14
- CRVS $5.28
- Resistance Level
- RXT $1.31
- CRVS $5.64
- Average True Range (ATR)
- RXT 0.08
- CRVS 0.30
- MACD
- RXT 0.01
- CRVS 0.03
- Stochastic Oscillator
- RXT 79.55
- CRVS 77.70
About RXT Rackspace Technology Inc.
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).